Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Defrancesco

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Nature Biotechnology|February 11, 2009
The cancer vaccine roller coasterBruce Goldman, Laura DeFrancesco
Nature Biotechnology|May 7, 2016
Nature Biotechnology's academic spinouts of 2015Aaron Bouchie, Laura DeFrancesco
Nature Biotechnology|October 7, 2022
Public biotech in 2021 - the numbersLaura DeFrancesco, Riku Lähteenmäki
Nature Biotechnology|May 10, 2011
Sequencing firms eye pathology labs as next big market opportunityLaura DeFrancesco, Nidhi Subbaraman
Nature Biotechnology|September 13, 2017
2Q17-Biotech stages a recoveryLaura DeFrancesco, Brady Huggett
Nature Biotechnology|September 11, 2019
Publisher Correction: Your DNA brokerLaura DeFrancesco, Ariel Klevecz
Nature Biotechnology|April 4, 2019
Focus on wearable sensorsLaura DeFrancesco, Irene Jarchum
Nature Biotechnology|November 9, 2007
The paper trail to commercializationJim Kling, Laura DeFrancesco
Nature Biotechnology|August 30, 2022
Decentralized investor communities gain traction in biotechLaura DeFrancesco, Ariel Klevecz
Nature Biotechnology|September 12, 2023
Public biotech in 2022 - the numbersLaura DeFrancesco, Riku Lähteenmäki
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Nature Biotechnology|February 11, 2009
The cancer vaccine roller coasterBruce Goldman, Laura DeFrancesco
Nature Biotechnology|May 7, 2016
Nature Biotechnology's academic spinouts of 2015Aaron Bouchie, Laura DeFrancesco
Nature Biotechnology|October 7, 2022
Public biotech in 2021 - the numbersLaura DeFrancesco, Riku Lähteenmäki
Nature Biotechnology|May 10, 2011
Sequencing firms eye pathology labs as next big market opportunityLaura DeFrancesco, Nidhi Subbaraman
Nature Biotechnology|September 13, 2017
2Q17-Biotech stages a recoveryLaura DeFrancesco, Brady Huggett
Nature Biotechnology|September 11, 2019
Publisher Correction: Your DNA brokerLaura DeFrancesco, Ariel Klevecz
Nature Biotechnology|April 4, 2019
Focus on wearable sensorsLaura DeFrancesco, Irene Jarchum
Nature Biotechnology|November 9, 2007
The paper trail to commercializationJim Kling, Laura DeFrancesco
Nature Biotechnology|August 30, 2022
Decentralized investor communities gain traction in biotechLaura DeFrancesco, Ariel Klevecz
Nature Biotechnology|September 12, 2023
Public biotech in 2022 - the numbersLaura DeFrancesco, Riku Lähteenmäki
Pageof 16